Clinical Trials | February 17, 2026
Roche’s Gazyva hits major milestone in rare kidney disease
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
The initiative, delivered in collaboration with Accenture, integrates digitally enabled operating models powered by advanced analytics and AI across the company’s procurement, manufacturing, and distribution networks
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
Iberdomide has the potential to be the first approved CELMoD agent
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
Subscribe To Our Newsletter & Stay Updated
